MicroRNA-targeted therapeutics for lung cancer treatment
- 28 November 2016
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Drug Discovery
- Vol. 12 (2) , 141-157
Abstract
Introduction: Lung cancer is one of the leading causes of cancer-related mortality worldwide. MicroRNAs (miRNAs) are endogenous non-coding small RNAs that repress the expression of a broad array of target genes. Many efforts have been made to therapeutically target miRNAs in cancer treatments using miRNA mimics and miRNA antagonists. Areas covered: This article summarizes the recent findings with the role of miRNAs in lung cancer, and discusses the potential and challenges of developing miRNA-targeted therapeutics in this dreadful disease. Expert opinion: The development of miRNA-targeted therapeutics has become an important anti-cancer strategy. Results from both preclinical and clinical trials of microRNA replacement therapy have shown some promise in cancer treatment. However, some obstacles, including drug delivery, specificity, off-target effect, toxicity mediation, immunological activation and dosage determination should be addressed. Several delivery strategies have been employed, including naked oligonucleotides, liposomes, aptamer-conjugates, nanoparticles and viral vectors. However, delivery remains a main challenge in miRNA-targeting therapeutics. Furthermore, immune-related serious adverse events are also a concern, which indicates the complexity of miRNA-based therapy in clinical settings.Keywords
Funding Information
- National Natural Science Foundation of China (31472191)
This publication has 149 references indexed in Scilit:
- Therapeutic Delivery of MicroRNA-29b by Cationic Lipoplexes for Lung CancerMolecular Therapy Nucleic Acids, 2013
- Long-term, efficient inhibition of microRNA function in mice using rAAV vectorsNature Methods, 2012
- Systemic Delivery of Tumor Suppressor microRNA Mimics Using a Neutral Lipid Emulsion Inhibits Lung Tumors in MiceMolecular Therapy, 2011
- RNA interference in the clinic: challenges and future directionsNature Reviews Cancer, 2010
- The elephant in the room: do microRNA-based therapies have a realistic chance of succeeding for brain tumors such as glioblastoma?Journal of Neuro-Oncology, 2010
- Emerging Roles for Natural MicroRNA SpongesCurrent Biology, 2010
- Nanoparticles Modified With Tumor-targeting scFv Deliver siRNA and miRNA for Cancer TherapyMolecular Therapy, 2010
- Systemic Delivery of Synthetic MicroRNA-16 Inhibits the Growth of Metastatic Prostate Tumors via Downregulation of Multiple Cell-cycle GenesMolecular Therapy, 2010
- Therapeutic microRNA Delivery Suppresses Tumorigenesis in a Murine Liver Cancer ModelCell, 2009
- Silencing of microRNAs in vivo with ‘antagomirs’Nature, 2005